Croda maintains course despite extra region volatility from US tariffs

Croda International PLC reported Q3 revenue of £424.7 million, up 4.4% (6.5% constant currency), representing a slight deceleration from H1 growth, with shares rising 1.3%. The chemicals group navigated a challenging trading environment marked by regional volatility from US trade tariffs impacting certain pharma, industrial, and agriculture markets, alongside low order book visibility. Despite these headwinds and flat pricing, Croda reiterated its full-year adjusted profit before tax guidance of £265 million to £295 million, attributing this to strong performance in beauty active ingredients and crop protection, coupled with being on track to deliver £25 million in cost savings this year as part of its ongoing transformation plan.

Analysis

Croda International PLC reported Q3 2025 revenue of £424.7 million, a 4.4% year-over-year increase (6.5% constant currency), which represents a deceleration from H1's 7% underlying growth. Despite this, shares rose 1.3%, indicating a mildly positive market reception to the company's resilience. This suggests investors are factoring in the company's strategic initiatives.

The trading environment remained challenging, with US trade tariffs creating regional volatility that impacted customer export sales in Asian pharma/industrial and Latin American agriculture markets. While sales volumes grew by low double digits, flat pricing and product mix effects continued to pressure margins. Growth was notably driven by strong performance in beauty active ingredients, fragrances, flavours, and a recovery in crop protection.

Crucially, Croda reiterated its full-year adjusted profit before tax guidance of £265 million to £295 million, even with expectations of continued challenging conditions and low order book visibility. This outlook is supported by the company being on track to deliver £25 million in cost savings this year, part of a broader £100 million transformation plan by 2027. The focus on cost optimization and innovation is key to navigating external pressures.

Key Decisions for Investors

• Investors should closely monitor Croda's execution of its £100 million cost savings program, as this is critical for margin resilience given flat pricing and trade-related headwinds
• Evaluate the ongoing impact of US trade tariffs on Croda's regional sales mix and customer demand, particularly in the affected pharma, industrial, and agriculture segments
• Assess the sustainability of growth in high-performing segments like beauty active ingredients and crop protection, which are currently offsetting broader market challenges and supporting the reiterated full-year guidance